Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 12;70(2):401–411. doi: 10.1161/HYPERTENSIONAHA.117.09113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors.

Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Effects of 8-Br (8-Bromo)-cAMP on Cx43 (connexin 43) phosphorylation in nonpregnant uterine artery endothelial cells (NP-UAECs) and pregnant uterine artery endothelial cells (P-UAECs). 8-Br-cGMP significantly increases both nonphosphorylated Cx43 S365 and pS368 levels. Western blot analysis showing the effects of 1 μmol/L and 1 mmol/L 8-Br-cGMP for 0 to 60 minutes or 12 hours in NP-UAECs vs P-UAECs on (A) nonphosphorylated Cx43 S365 levels detected by the Cx43 C-terminus (CT1) antibody, (B) Cx43 pS368 phosphorylation levels, (C) total Cx43 levels, and (D) Cx43 S365 and pS368 phosphorylation sites normalized to total Cx43 only for P-UAECs treated with 1 mmol/L 8-Br-cGMP. *, Increase (P<0.05, n=4) of cyclic nucleotide treatment vs untreated control. t, Increase (P<0.05, n=4) of Cx43 phosphorylation in 1 mmol/L vs 1 μmol/L treatment. #, Increase (P<0.05, n=4) of Cx43 phosphorylation in NP-UAEC- vs P-UAEC-treated cells.